| Shanna Gamble, FNP-C | |
|
3541 Balboa Bch, Abilene, TX 79606-5659 | |
| (325) 201-2984 | |
| Not Available |
| Full Name | Shanna Gamble |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 5 Years |
| Location | 3541 Balboa Bch, Abilene, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043859093 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | AP1043859093 (Texas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| C, L And W Pllc | 6709032295 | 15 |
News Archive
\VAYA Pharma announced the availability of Vayarin in pharmacies throughout North Carolina, South Carolina and Texas for children suffering with Attention-Deficit / Hyperactivity Disorder (ADHD).
In the wake of a recent FDA statement linking breast implants to a rare cancer called anaplastic large cell lymphoma, a newly updated algorithm provides plastic surgeons with guidance in managing women with breast lumps or swelling after breast augmentation.
Sosei Group Corporation, today announces that NVA237 (glycopyrronium bromide), a long-acting muscarinic antagonist (LAMA) being investigated as a once-daily treatment for chronic obstructive pulmonary disease (COPD), has been filed by Novartis for marketing authorisation with the European Medicines Agency (EMA), under the brand-name Seebri Breezhaler, triggering a $5m milestone payment to Sosei.
Research staff from the Universitat Jaume I in the fields of information technology, psychology and business have developed a monitoring system based on indoor location using mobile devices.
Thousands of infants each year have exposure to opioids before they are born. Over half of these infants are born with withdrawal symptoms severe enough to require opioid replacement treatment in the nursery. Such treatment is associated with long hospital stays which interferes with maternal/infant bonding. Now, a team of researchers at Thomas Jefferson University has tested a semi-synthetic opioid they say has the potential to improve the treatment of these newborns, which could save hundreds of millions in healthcare costs annually if future tests continue to show benefit.
› Verified 1 days ago
| Entity Name | C, L And W Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619235629 PECOS PAC ID: 6709032295 Enrollment ID: O20120816000562 |
News Archive
\VAYA Pharma announced the availability of Vayarin in pharmacies throughout North Carolina, South Carolina and Texas for children suffering with Attention-Deficit / Hyperactivity Disorder (ADHD).
In the wake of a recent FDA statement linking breast implants to a rare cancer called anaplastic large cell lymphoma, a newly updated algorithm provides plastic surgeons with guidance in managing women with breast lumps or swelling after breast augmentation.
Sosei Group Corporation, today announces that NVA237 (glycopyrronium bromide), a long-acting muscarinic antagonist (LAMA) being investigated as a once-daily treatment for chronic obstructive pulmonary disease (COPD), has been filed by Novartis for marketing authorisation with the European Medicines Agency (EMA), under the brand-name Seebri Breezhaler, triggering a $5m milestone payment to Sosei.
Research staff from the Universitat Jaume I in the fields of information technology, psychology and business have developed a monitoring system based on indoor location using mobile devices.
Thousands of infants each year have exposure to opioids before they are born. Over half of these infants are born with withdrawal symptoms severe enough to require opioid replacement treatment in the nursery. Such treatment is associated with long hospital stays which interferes with maternal/infant bonding. Now, a team of researchers at Thomas Jefferson University has tested a semi-synthetic opioid they say has the potential to improve the treatment of these newborns, which could save hundreds of millions in healthcare costs annually if future tests continue to show benefit.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Shanna Gamble, FNP-C 3541 Balboa Bch, Abilene, TX 79606-5659 Ph: () - | Shanna Gamble, FNP-C 3541 Balboa Bch, Abilene, TX 79606-5659 Ph: (325) 201-2984 |
News Archive
\VAYA Pharma announced the availability of Vayarin in pharmacies throughout North Carolina, South Carolina and Texas for children suffering with Attention-Deficit / Hyperactivity Disorder (ADHD).
In the wake of a recent FDA statement linking breast implants to a rare cancer called anaplastic large cell lymphoma, a newly updated algorithm provides plastic surgeons with guidance in managing women with breast lumps or swelling after breast augmentation.
Sosei Group Corporation, today announces that NVA237 (glycopyrronium bromide), a long-acting muscarinic antagonist (LAMA) being investigated as a once-daily treatment for chronic obstructive pulmonary disease (COPD), has been filed by Novartis for marketing authorisation with the European Medicines Agency (EMA), under the brand-name Seebri Breezhaler, triggering a $5m milestone payment to Sosei.
Research staff from the Universitat Jaume I in the fields of information technology, psychology and business have developed a monitoring system based on indoor location using mobile devices.
Thousands of infants each year have exposure to opioids before they are born. Over half of these infants are born with withdrawal symptoms severe enough to require opioid replacement treatment in the nursery. Such treatment is associated with long hospital stays which interferes with maternal/infant bonding. Now, a team of researchers at Thomas Jefferson University has tested a semi-synthetic opioid they say has the potential to improve the treatment of these newborns, which could save hundreds of millions in healthcare costs annually if future tests continue to show benefit.
› Verified 1 days ago
Jewel Monique Trancoso, APRN, FNP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2600 Ivanhoe Ln Apt 204, Abilene, TX 79605 Phone: 325-513-7293 | |
Brandon M. Goetz, N.P. Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1900 Pine St, Abilene, TX 79601 Phone: 325-670-2151 Fax: 405-321-4603 | |
Ana Maria Argumaniz, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1749 Pine St, Abilene, TX 79601 Phone: 325-696-0600 | |
Lauren Brooke Terrell, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 950 N 19th St Ste 200, Abilene, TX 79601 Phone: 325-670-5320 Fax: 325-670-5324 | |
Ms. Elizabeth Webber, FNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 818 Lexington Ave, Abilene, TX 79605 Phone: 325-696-0212 | |
Richard Sankara Musonera, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1749 Pine St, Abilene, TX 79601 Phone: 325-696-0600 Fax: 325-676-3873 | |
Bailey Ann Estes, APRN-CNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1210 N 18th St, Abilene, TX 79601 Phone: 325-207-4734 |